Fisher & Paykel Healthcare Corporation Limited logo

Notification of Issue of Securities

Capital Change30 August 2019FPHHealthcare

Page 1 of 2
30 August 2019

Issue of ordinary shares

This notice is given under NZX Listing Rule 3.13.1 and relates to the issue of ordinary shares in Fisher &

Paykel Healthcare Corporation Limited (“FPH”) under the Fisher & Paykel Healthcare 2003 Share Option

Plan.


This notice is given in reliance on a waiver from NZX Listing Rule 3.13.1 granted by NZX on 6 August 2019

that allows FPH, subject to certain conditions, to disclose the issue of FPH shares under FPH’s employee

share purchase schemes within 10 business days of issue.


Section 1: issuer information

Name of issuer Fisher & Paykel Healthcare Corporation Limited

NZX ticker code FPH

Class of Financial Product Ordinary shares

ISIN NZFAPE0001S2

Section 2: capital change details

Number of issuances to which this

notice relates

Eight

Number issued (1) 1,743 on 19 August 2019

(2) 6,225 on 20 August 2019

(3) 3,817 on 21 August 2019

(4) 3,390 on 22 August 2019

(5) 1,090 on 23 August 2019

(6) 7,463 on 26 August 2019

(7) 11,213 on 27 August 2019

(8) 6,643 on 28 August 2019

Total issued: 41,584 shares

Nominal value (if any) Not applicable

Issue price (1) NZD4.88 (1,743 shares)

(2) NZD4.88 (6,225 shares)

(3) NZD4.88 (3,817 shares)

(4) NZD4.88 (3,390 shares)

(5) NZD4.88 (1,090 shares)

(6) NZD4.88 (7,463 shares)

(7) NZD4.88 (6,002 shares); NZD7.23 (5,211 shares)

(8) NZD4.88 (6,643 shares)

Nature of the payment Not applicable

Amount paid up (if not in full) In full

Percentage of total class of Financial

Products issued

(1) 0.00030%

(2) 0.00108%

(3) 0.00067%

(4) 0.00059%

(5) 0.00019%

(6) 0.00130%

(7) 0.00195%

(8) 0.00116%

For an issue of Convertible Financial

Products or Options, the principal

terms of Conversion

Not applicable

Page 2 of 2
Reason for issue

(1) Cancellation of 1,300 options and issue of 903 ordinary shares;

Exercise of 840 options under the FPH Share Option Plan and

issue of 840 ordinary shares.

(2) Cancellation of 5,070 options and issue of 3,515 ordinary shares;

Exercise of 2,710 options under the FPH Share Option Plan and

issue of 2,710 ordinary shares.

(3) Cancellation of 2,780 options and issue of 1,927 ordinary shares;

Exercise of 1,890 options under the FPH Share Option Plan and

issue of 1,890 ordinary shares.

(4) Cancellation of 4,890 options and issue of 3,390 ordinary shares.

(5) Exercise of 1,090 options under the FPH Share Option Plan and

issue of 1,090 ordinary shares.

(6) Cancellation of 8,780 options and issue of 6,073 ordinary shares;

Exercise of 1,390 options under the FPH Share Option Plan and

issue of 1,390 ordinary shares.

(7) Cancellation of 11,450 options and issue of 6,873 ordinary

shares; Exercise of 4,340 options under the FPH Share Option

Plan and issue of 4,340 ordinary shares.

(8) Cancellation of 9,770 options and issue of 6,643 ordinary shares.


All cancellations are under the FPH Share Option Plan Cancellation

Facility

Total number of Financial Products of

the Class after the issue (excluding

Treasury Stock) and the total number

of Financial Products of the Class held

as Treasury Stock after the issue.

(1) 573,931,605

(2) 573,937,830

(3) 573,941,647

(4) 573,945,037

(5) 573,946,127

(6) 573,953,590

(7) 573,964,803

(8) 573,971,446

Total number of ordinary shares on issue as at the date of this notice

after the issues disclosed in this notice: 573,971,446

In the case of an acquisition of shares,

whether those shares are to be held as

treasury stock

Not applicable

Specific authority for the issue Directors’ resolution, Listing Rule 4.6

Terms or details of the issue The ordinary shares issued rank pari passu with the existing ordinary

shares

Date of issue (1) 19 August 2019

(2) 20 August 2019

(3) 21 August 2019

(4) 22 August 2019

(5) 23 August 2019

(6) 26 August 2019

(7) 27 August 2019

(8) 28 August 2019

Section 3: authority for this announcement

Name of person authorised to make

this announcement

Marcus Driller

Contact phone number +64 9 574 0110

Contact email address marcus.driller@fphcare.co.nz

Date of release via MAP 30 August 2019

---

+ See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page 1

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B


New issue announcement,

application for quotation of additional securities

and agreement


Information or documents not available now must be given to ASX as soon as available. Information and

documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05,

01/08/12, 04/03/13



Name of entity

Fisher & Paykel Healthcare Corporation Limited


ABN

098 026 281



We (the entity) give ASX the following information.



Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).


1

+

Class of

+

securities issued or to

be issued


Ordinary shares



2 Number of

+

securities issued or

to be issued (if known) or

maximum number which may be

issued


41,584


3 Principal terms of the
+

securities

(e .g. if options, exercise price and

expiry date; if partly paid

+

securities, the amount

outstanding and due dates for

payment; if

+

convertible

securities, the conversion price

and dates for conversion)

Employees cancelling options granted in August

2014 and September 2015 under the Fisher & Paykel

Healthcare 2003 Share Option Plan. All cancellations

are pursuant to the Company’s Cancellation Facility.


Employees exercising options granted under the

Fisher & Paykel Healthcare Option Plan in August

2014.


(1) 19 August 2019

- 1,300 options were cancelled – 903 ordinary

shares were issued ^.

- Issue of 840 ordinary shares on exercise of 840

options granted^^.

(2) 20 August 2019

- 5,070 options were cancelled - 3,515 ordinary

shares were issued ^.

- Issue of 2,710 ordinary shares on exercise of

2,710 options granted^^.

(3) 21 August 2019

- 2,780 options were cancelled - 1,927 ordinary

shares were issued^.

- Issue of 1,890 ordinary shares on exercise of

1,890 options granted^^.

(4) 22 August 2019

- 4,890 options were cancelled - 3,390 ordinary

shares were issued^.

(5) 23 August 2019

- Issue of 1,090 ordinary shares on exercise of

1,090 options granted ^^.

(6) 26 August 2019

- 8,780 options were cancelled - 6,073 ordinary

shares were issued ^.

- Issue of 1,390 ordinary shares on exercise of

1,390 options^^.

(7) 27 August 2019

- 11,450 options were cancelled - 6,873 ordinary

shares were issued^.

- Issue of 4,340 ordinary shares following

exercise of 4,340 options granted under the

Fisher & Paykel Healthcare Option Plan in

August 2014 based on exercise prices of

NZD4.88 and NZD7.23.

(8) 28 August 2019

- 9,770 options were cancelled - 6,643 ordinary

shares were issued ^.



^ shares issued in consideration of the cancellation

of those options and are equal in value to the gain on

the options (such gain being calculated based on

exercise prices of NZD4.88 or NZD7.23).

^^ shares issued under the Fisher & Paykel

Healthcare Option Plan in August 2014 based on an

exercise price of NZD4.88



+ See chapter 19 for defined terms.


04/03/2013 Appendix 3B Page 3





4 Do the

+

securities rank equally in

all respects from the

+

issue date

with an existing

+

class of quoted

+

securities?


If the additional

+

securities do

not rank equally, please state:

• the date from which they do

• the extent to which they

participate for the next

dividend, (in the case of a

trust, distribution) or interest

payment

• the extent to which they do

not rank equally, other than

in relation to the next

dividend, distribution or

interest payment

Yes



5 Issue price or consideration


(1) 19 August 2019 – NZD4.88 per ordinary share

(2) 20 August 2019 – NZD4.88 per ordinary share

(3) 21 August 2019 – NZD4.88 per ordinary share

(4) 22 August 2019 – NZD4.88 per ordinary share

(5) 23 August 2019 – NZD4.88 per ordinary share

(6) 26 August 2019 – NZD4.88 per ordinary share

(7) 27 August 2019 – NZD4.88 per ordinary share

(6,002 shares) and NZD7.23 per ordinary share

(5,211 shares)

(8) 28 August 2019 – NZD4.88 per ordinary share



6 Purpose of the issue

(If issued as consideration for

the acquisition of assets, clearly

identify those assets)







Issued to employees under the Fisher & Paykel

Healthcare 2003 Share Option Plan.


This combined Appendix 3B is given in reliance on a

wavier from NZX Listing Rule 3.13.1 granted by NZX

on 6 August 2019 that allows FPH, subject to certain

conditions, to disclose the issue of FPH shares under

FPH’s employee share purchase schemes within 10

business days of issue. This waiver has been

acknowledged by ASX.




6a Is the entity an

+

eligible entity

that has obtained security holder

approval under rule 7.1A?


If Yes, complete sections 6b – 6h

in relation to the

+

securities the

subject of this Appendix 3B, and

comply with section 6i

No


6b The date the security holder
resolution under rule 7.1A was

passed




6c Number of

+

securities issued

without security holder approval

under rule 7.1




6d Number of

+

securities issued

with security holder approval

under rule 7.1A




6e Number of

+

securities issued

with security holder approval

under rule 7.3, or another

specific security holder approval

(specify date of meeting)





6f Number of

+

securities issued

under an exception in rule 7.2




6g If

+

securities issued under rule

7.1A, was issue price at least

75% of 15 day VWAP as

calculated under rule 7.1A.3?

Include the

+

issue date and both

values. Include the source of the

VWAP calculation.




6h If

+

securities were issued under

rule 7.1A for non-cash

consideration, state date on

which valuation of consideration

was released to ASX Market

Announcements




6i Calculate the entity’s remaining

issue capacity under rule 7.1 and

rule 7.1A – complete Annexure 1

and release to ASX Market

Announcements




7

+

Issue dates

Note: The issue date may be prescribed by ASX

(refer to the definition of issue date in rule

19.12). For example, the issue date for a pro

rata entitlement issue must comply with the

applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

(1) 1,743 on 19 August 2019

(2) 6,225 on 20 August 2019

(3) 3,817 on 21 August 2019

(4) 3,390 on 22 August 2019

(5) 1,090 on 23 August 2019

(6) 7,463 on 26 August 2019

(7) 11,213 on 27 August 2019

(8) 6,643 on 28 August 2019



+ See chapter 19 for defined terms.


04/03/2013 Appendix 3B Page 5


Number

+

Class

8 Number and

+

class of all

+

securities quoted on ASX

(including the

+

securities in

section 2 if applicable)




573,971,446 Ordinary Shares

Part 2 - Pro rata issue

9 Number and +class of all

+securities not quoted on

ASX (including the

securities in clause 2 if

applicable


Number Class



FPHAY 121,071 ESRs expiring 13 September

2021, exercise price NZDnil



FPHAW 210,623 PSRs expiring 13 September

2023, exercise price NZDnil



FPHAT 389,201 PSRs expiring 5 September

2022, exercise price NZDnil


FPHAJ 358,965 PSRs expiring 6 September

2021, exercise price NZDnil


FPHAX 650,792 Options expiring 13 September

2023, exercise price NZD14.91


FPHAV 30,565 Options expiring 7 September

2022, exercise price NZD11.81


FPHAU 1,038,436 Options expiring 5 September

2022, exercise price NZD11.81


FPHAB 1,118,854 Options expiring 6 September

2021, exercise price NZD9.82


FPHAI 28,910 Options expiring 11 September

2020, exercise price NZD7.23



FPHAG 577,369 Options expiring 8 September

2020, exercise price NZD7.23



FPHAE 0 Options expiring 28 August

2019, exercise price NZD4.88



10 Dividend policy (in the case of a

trust, distribution policy) on the

increased capital (interests)

No change

11 Is security holder approval

required?





12 Is the issue renounceable or non-

renounceable?




13 Ratio in which the

+

securities will

be offered




14

+

Class of

+

securities to which the

offer relates





15

+

Record date to determine

entitlements





16 Will holdings on different

registers (or subregisters) be

aggregated for calculating

entitlements?




+ See chapter 19 for defined terms.


04/03/2013 Appendix 3B Page 7

17 Policy for deciding entitlements in

relation to fractions





18 Names of countries in which the

entity has security holders who

will not be sent new offer

documents

Note: Security holders must be told how their

entitlements are to be dealt with.

Cross reference: rule 7.7.




19 Closing date for receipt of

acceptances or renunciations


+ See chapter 19 for defined terms.


Appendix 3B Page 8 04/03/2013


20 Names of any underwriters






21 Amount of any underwriting fee

or commission




22 Names of any brokers to the issue






23 Fee or commission payable to the

broker to the issue




24 Amount of any handling fee

payable to brokers who lodge

acceptances or renunciations on

behalf of security holders




25 If the issue is contingent on

security holders’ approval, the

date of the meeting




26 Date entitlement and acceptance

form and offer documents will be

sent to persons entitled




27 If the entity has issued options,

and the terms entitle option

holders to participate on exercise,

the date on which notices will be

sent to option holders




28 Date rights trading will begin (if

applicable)




29 Date rights trading will end (if

applicable)






30 How do security holders sell their

entitlements in full through a

broker?




31 How do security holders sell part

of their entitlements through a

broker and accept for the

balance?




+ See chapter 19 for defined terms.


04/03/2013 Appendix 3B Page 9


32 How do security holders dispose

of their entitlements (except by

sale through a broker)?




33

+

Issue date






Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities


34 Type of

+

securities

(tick one)


(a)


+

Securities described in Part 1



(b)


All other

+

securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid,

employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible

securities


Entities that have ticked box 34(a)


Additional securities forming a new class of securities



Tick to indicate you are providing the information or

documents



35


If the

+

securities are

+

equity securities, the names of the 20 largest holders of the

additional

+

securities, and the number and percentage of additional

+

securities

held by those holders



36


If the

+

securities are

+

equity securities, a distribution schedule of the additional

+

securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over



37


A copy of any trust deed for the additional

+

securities


+ See chapter 19 for defined terms.


Appendix 3B Page 10 04/03/2013


Entities that have ticked box 34(b)


38 Number of

+

securities for which

+

quotation is sought






39

+

Class of

+

securities for which

quotation is sought





40 Do the

+

securities rank equally in

all respects from the

+

issue date

with an existing

+

class of quoted

+

securities?


If the additional

+

securities do not

rank equally, please state:

• the date from which they do

• the extent to which they

participate for the next

dividend, (in the case of a trust,

distribution) or interest

payment

• the extent to which they do not

rank equally, other than in

relation to the next dividend,

distribution or interest

payment




41 Reason for request for quotation

now

Example: In the case of restricted securities, end

of restriction period


(if issued upon conversion of

another

+

security, clearly identify

that other

+

security)






Number

+

Class

42 Number and

+

class of all

+

securities quoted on ASX

(including the

+

securities in clause

38)







+ See chapter 19 for defined terms.


04/03/2013 Appendix 3B Page 11



Quotation agreement


1

+

Quotation of our additional

+

securities is in ASX’s absolute discretion. ASX

may quote the

+

securities on any conditions it decides.


2 We warrant the following to ASX.


• The issue of the

+

securities to be quoted complies with the law and is

not for an illegal purpose.


• There is no reason why those

+

securities should not be granted

+

quotation.


• An offer of the

+

securities for sale within 12 months after their issue

will not require disclosure under section 707(3) or section 1012C(6) of

the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able

to give this warranty


• Section 724 or section 1016E of the Corporations Act does not apply to

any applications received by us in relation to any

+

securities to be

quoted and that no-one has any right to return any

+

securities to be

quoted under sections 737, 738 or 1016F of the Corporations Act at the

time that we request that the

+

securities be quoted.


• If we are a trust, we warrant that no person has the right to return the

+

securities to be quoted under section 1019B of the Corporations Act at

the time that we request that the

+

securities be quoted.


3 We will indemnify ASX to the fullest extent permitted by law in respect of any

claim, action or expense arising from or connected with any breach of the

warranties in this agreement.


4 We give ASX the information and documents required by this form. If any

information or document is not available now, we will give it to ASX before

+

quotation of the

+

securities begins. We acknowledge that ASX is relying on the

information and documents. We warrant that they are (will be) true and

complete.



Sign here: ................................................ Date: 30 August 2019

Company Secretary


Print name: Marcus Driller


== == == == ==

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.